Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Summary

This study is being done because there are currently no approved and no commonly working targeted therapies in anaplastic thyroid cancer (ATC). This is an area of urgent need for patients, not just for approved treatments but also rationally-designed clinical trials designed specifically for ATC. Patients diagnosed with anaplastic thyroid cancer have a very high likelihood of dying because of their disease. As such there is a clear need for improving therapy for ATC.

Timeline

Start

2016-10

Primary completion

2020-10

Completion

2021-10

Drugs

Indications